The pathogenesis and treatment of chronic asthma (CA) have always received extensive attention. After decades of accumulation, Creative Biolabs can provide customers all over the world with IgE and CA research related information and services to help your project proceed smoothly.
Introduction of CA
Asthma is a common chronic inflammatory disease of the airway, which is characterized by intermittent chest symptoms and variable airway obstruction. In recent years, asthma has gradually been regarded as a chronic disease with significant clinical heterogeneity and different etiologies over time. Generally speaking, asthma is divided into two phenotypes, external and internal. Exogenous asthma is characterized by an allergy to foreign molecules, such as pollen and protein. Endogenous asthma is related to many factors, such as asthma induced by chronic sinusitis, acute bronchitis, cold or exercise. CA is actually the late manifestation of various types of asthma, and their triggering factors such as infection or inhalation of allergens are also difficult to determine. CA may be related to the changes in bronchial lines caused by repeated onsets.
Fig.1 Asthma under the Microscope. (Lambrecht, 2019)
IgE in CA
Immunoglobulin E (IgE) is inseparable from the development of allergic diseases. In allergic individuals, exposure to allergens induces a series of complex reactions, leading to the production of allergen-specific IgE. IgE attaches to inflammatory cells by connecting to Fc receptors. Further exposure to allergens induces cross-bridges between the allergens and IgE on the surface of these effector cells, which causes the inflammatory cells to release pro-inflammatory mediators. In some patients with allergic asthma, higher than normal levels of IgE may increase persistent airway inflammation and bronchial hyperresponsiveness, which may be caused by persistent allergic activation.
Therapy for CA
At present, asthma still has a great impact on human life and it is related to severe mortality and morbidity. Inhaled steroids and bronchodilators are currently widely used treatment strategies. It is worth noting that the methods have a good therapeutic effect on mild and moderate asthma, but patients with severe asthma usually require oral steroids and other immunosuppressive programs accompanied by side effects. With the in-depth research on the pathology of asthma, treatments based on anti-IgE monoclonal antibodies have gradually attracted increasing attention. A recombinant humanized monoclonal antibody has been successfully used in the treatment of asthma. This antibody can recognize IgE at the same Fc site as the receptor binding site. This anti-IgE antibody binds to free IgE to form a complex to block the interaction between IgE and effector cells. In addition, the complex formed after treatment is very small and cannot trigger complement activation or cause immune complex-mediated pathology. The most important thing is that the monoclonal antibody can reduce the serum free IgE concentration after injection, thereby significantly reducing the asthma response after inhaling allergens.
As a reputable supplier, Creative Biolabs has been equipped to provide our customers with accurate IgE and CA research related backgrounds and solutions. If you have any difficulties with IgE and CA projects, please contact us for more details.
Reference
- Lambrecht, B. N.; et al. The cytokines of asthma. Immunity. 2019, 50(4): 975-991.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
